目的 探讨精脒(Spermidine)对老龄小鼠股骨微结构的影响。方法 选取20只21月龄C57老龄小鼠随机分为对照组(Vehicle,n=10)和实验组(Spermidine,n=10),Spermidine组在饮水中按3 mmol/L的浓度加入Spermidine,干预时间为12周。每周测量各组小鼠的体重;实验结束时,检测血、尿中骨代谢生化指标,micro-CT测量分析股骨形态学指标。结果 与Vehicle组相比,Spermidine 对老龄小鼠的体重无影响;骨源性碱性磷酸酶(alkaline phosphatase, ALP)水平显著升高,差异有统计学意义(P＜0.05);可明显提高骨小梁相对骨体积(trabecular bone volume per tissue volume, Tb.BV/TV)、骨小梁数目(trabecular number,Tb.N)、骨小梁厚度(trabecular thickness,Tb.Th)和骨密度(bone mineral density, BMD),降低骨小梁间隙(trabecular separation, Tb.Sp),差异均有统计学意义(P＜0.05)。结论 Spermidine能缓解小鼠老龄性骨质疏松。
Abstract
Objective To investigate the effects of spermidine on bone microstructure of femurs of senile mice. Methods Twenty 21-month-old C57 mice were randomly divided into the vehicle group (n=10 ) and spermidine group (3 mmol/L spermidine in drinking water, n=10). Body weight was measured weekly during the study. After 12 weeks of intervention, biochemical indexes of bone metabolism in serum and urine were tested and histomorphometry of femurs was measured by micro-CT (microcomputed tomography). Results Compared with the vehicle mice, spermidine had no effect on the weight of senile mice. Spermidine intervention significantly increased serum levels of ALP (P＜0.05), elevated the trabecular bone volume per tissue volume (Tb.BV/TV), trabecular number (Tb.N), trabecular thickness (Tb.Th)and bone mineral density (BMD), and reduced trabecular separation (Tb.Sp). Conclusions Spermidine attenuates age-associated osteoporosis in senile mice.
关键词
精脒 /
碱性磷酸酶 /
老龄鼠 /
骨质疏松
Key words
spermidine /
alkaline phosphatase /
senile mice /
osteoporosis
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] Tella S H, Gallagher J C. Prevention and treatment of postmenopausal osteoporosis[J]. J Steroid Biochem Mol Biol, 2014,142:155-170.
[2] Jerome C P, Boyce R. Bone therapeutics: safety considerations, session summary[J]. Toxicol Pathol, 2017,45(7):855-858.
[3] 夏蓉晖,聂 颖,赵绵松,等. 某高校退休职工骨质疏松现状调查及影响因素分析[J]. 武警医学, 2019,30(1):19-21.
[4] 朱 彪,焦 婷,赵 刚,等. GDF11抑制老龄鼠骨形成的实验研究[J]. 牙体牙髓牙周病学杂志, 2017,27(11):623-628.
[5] Goode S C, Beshears J L, Goode R D, et al. Putting the brakes on breaks: osteoporosis screening and fracture prevention[J]. Geriatr Orthop Surg Rehabil, 2017,8(4):238-243.
[6] Ding Y, Jiang H, Meng B, et al. Sweroside-mediated mTORC1 hyperactivation in bone marrow mesenchymal stem cells promotes osteogenic differentiation[J]. J Cell Biochem, 2019,120(9):16025-16036.
[7] Eisenberg T, Abdellatif M, Schroeder S, et al. Cardioprotection and lifespan extension by the natural polyamine spermidine[J]. Nat Med, 2016,22(12):1428-1438.
[8] Tong D, Hill J A. Spermidine promotes cardioprotective autophagy[J]. Circ Res, 2017,120(8):1229-1231.
[9] Gao M, Zhao W, Li C, et al. Spermidine ameliorates non-alcoholic fatty liver disease through regulating lipid metabolism via AMPK[J]. Biochem Biophys Res Commun, 2018,505(1):93-98.
[10] Gupta V K, Scheunemann L, Eisenberg T, et al. Restoring polyamines protects from age-induced memory impairment in an autophagy-dependent manner[J]. Nat Neurosci, 2013,16(10):1453-1460.
[11] Madeo F, Bauer M A, Carmona G D, et al. Spermidine: a physiological autophagy inducer acting as an anti-aging vitamin in humans?[J]. Autophagy, 2019,15(1):165-168.
[12] 翟 羽,焦 婷,郭红延,等. GDF11抑制小鼠BMSCs成骨分化的机制研究[J]. 临床口腔医学杂志, 2020,36(4):195-198.
[13] 郭 滨,甄国朋,杨海青,等. Irisin对老龄性骨质疏松小鼠骨代谢的影响及机制研究[J]. 解放军医药杂志, 2019,31(12):23-28.
[14] Liu W, Zhou L, Zhou C, et al. GDF11 decreases bone mass by stimulating osteoclastogenesis and inhibiting osteoblast differentiation[J]. Nat Commun, 2016,7:12794.
[15] Yamamoto T, Hinoi E, Fujita H, et al. The natural polyamines spermidine and spermine prevent bone loss through preferential disruption of osteoclastic activation in ovariectomized mice[J]. Br J Pharmacol, 2012,166(3):1084-1096.
[16] Yamada T, Park G, Node J, et al. Daily intake of polyamine-rich Saccharomyces cerevisiae S 631 prevents osteoclastic activation and bone loss in ovariectomized mice[J]. Food Sci Biotechnol, 2019,28(4):1241-1245.
[17] Labouesse M A, Gertz E R, Piccolo B D, et al. Associations among endocrine, inflammatory, and bone markers, body composition and weight loss induced bone loss[J]. Bone, 2014,64:138-146.
[18] Fogelholm G M, Sievánen H T, Kukkonen T K, et al. Bone mineral density during reduction, maintenance and regain of body weight in premenopausal, obese women[J]. Osteoporos Int, 2001,12(3):199-206.
[19] 荀靖琼,李 婵,刘美璐,等. 阿托伐他汀对超老年去卵巢大鼠骨密度、骨微结构及骨生物力学性能的影响[J]. 中华骨质疏松和骨矿盐疾病杂志, 2021,14(2):162-168.
[20] Rokidi S, Paschalis E P, Klaushofer K, et al. Organic matrix quality discriminates between age and BMD-matched fracturing versus non-fracturing post-menopausal women: a pilot study[J]. Bone, 2019,127:207-214.
[21] Ott S M. Cortical or trabecular bone: what's the difference?[J]. Am J Nephrol, 2018,47(6):373-375.
[22] Khosla S, Hofbauer L C. Osteoporosis treatment: recent developments and ongoing challenges[J]. Lancet Diabetes Endocrinol, 2017,5(11):898-907.
基金
中国博士后科学基金资助项目(2019T120977)
PDF(1389 KB)
